1. Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?

   • Raffaele Califano
   • Ourania Romanidou
   • Fiona Blackhall

   Current Opinion 29 April 2016 Pages: 831 - 840

2. Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease

   • S. N. Salam
   • A. Khwaja
   • M. E. Wilkie

   Therapy in Practice 03 May 2016 Pages: 841 - 852

   

3. Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

   • Philippe Moreau
   • Niels W. C. J. van de Donk
   • María-Victoria Mateos

   Therapy in Practice 25 April 2016 Pages: 853 - 867

4. Eltrombopag: A Review in Paediatric Chronic Immune Thrombocytopenia

   • Celeste B. Burness
   • Gillian M. Keating
   • Karly P. Garnock-Jones

   Adis Drug Evaluation 05 May 2016 Pages: 869 - 878

   

5. Gabapentin Enacarbil: A Review in Restless Legs Syndrome

   • Esther S. Kim
   • Emma D. Deeks

   Adis Drug Evaluation 04 May 2016 Pages: 879 - 887

6. Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia

   • Lesley J. Scott

   Adis Drug Evaluation 18 May 2016 Pages: 889 - 900

7. Ixekizumab: First Global Approval

   • Anthony Markham

   AdisInsight Report 20 April 2016 Pages: 901 - 905

   

8. Reslizumab: First Global Approval

   • Anthony Markham

   AdisInsight Report 28 April 2016 Pages: 907 - 911

   

9. Erratum to: Management Strategies for Clopidogrel Hypersensitivity

   • Craig J. Beavers
   • Nicolas W. Carris
   • Kathryn M. Ruf

   Erratum 29 April 2016 Pages: 913 - 913